Share Twitter LinkedIn Facebook Email Amrita Krishnan, MD, from The Judy and Bernard Briskin Center For Multiple Myeloma Research talks about the antibody drug conjugate against BCMA – 60% response rate in refractory myeloma at MOASCs Spotlight On® Hematology in Huntington Beach.
Advances in Acute Lymphoblastic Leukemia (ALL) Treatment: A Focus on Targeted Therapies – Elias Jabbour, MD Acute Lymphoblastic Leukemia 4 Mins Read
FDA grants accelerated approval to ponatinib (ICLUSIG®) with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia Acute Lymphoblastic Leukemia 3 Mins Read
FDA Approves Inotuzumab Ozogamicin (BESPONSA) for Acute Lymphoblastic Leukemia in Pediatric Patients [Exclusive Video] Acute Lymphoblastic Leukemia 3 Mins Read